Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019-12-01
Colecção:Frontiers in Oncology
Assuntos:
pancreatic cancer
tyrosine kinase inhibitors
RON receptor tyrosine kinase
MET receptor tyrosine kinase
prognosis biomarker
therapeutic target
Acesso em linha:https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados